Skip to content

CG Oncology

US · CGON #1929 by market cap Listed 2024
79.47 -2.43 -2.97%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 81.03 -1.06%
After-hours 79.50 +0.04%
Overnight 82.00 +0.12%
84.7853.7279.472026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on CGON?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +48.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days D → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Gross margin -15.0% Better than 1%
Operating margin -4,722.1% Better than 1%
Net margin -3,985.0% Better than 1%
Return on equity -21.7% Better than 16%
Return on invested capital -25.6% Better than 11%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -0.4% Better than 73%
6-month return 23.7% Better than 86%
12-month return (ex latest month) 45.4% Better than 81%
Distance below 52-week high 15.4% Better than 70%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 24.6x Better than 99%
Debt to assets 0.9% Better than 93%
Interest coverage -35,442.0x Better than 0%
Analyst View B-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 13.3% Better than 19%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +6.81%
1M +28.32%
3M +2.40%
6M +22.71%
YTD +91.40%
1Y +95.21%

Key statistics

Price & volume

Prev close
81.90
Open
80.32
Day range
79.21 - 83.16
Avg price
80.74
Volume
1.67M
Turnover
135.18M
Amplitude
4.82%
52-week range
37.01 - 93.95

Valuation

P/E
-38.21
P/E (TTM)
-28.79
P/B
7.16
EPS
-2.08
Net profit
-185.78M
Net assets
990.99M

Share structure

Market cap
7.10B
Float cap
5.48B
Shares out
89.32M
Float shares
68.95M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2024-01-25
52-week range 75% of range
37.01 93.95

15.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-22.27M net over the window

Short interest

Shares short
9.22M
As of
2026-10-30

Frequently asked questions

What is the current stock price of CG Oncology (CGON)?

CG Oncology last traded at 79.47. This page shows a periodic quote snapshot. Check the displayed quote time.

What is CG Oncology's market cap?

About 7.10B.

What is the P/E ratio of CG Oncology?

The trailing twelve-month P/E is -28.79. The Valuation tab shows it against the stock's own five-year range.

Does CG Oncology pay a dividend?

CG Oncology does not currently pay a regular dividend.

Is CG Oncology a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 90.00, which implies 13.3% upside from the current price. This is not investment advice.

What is CG Oncology's StockVane Quant Rating?

The StockVane Momentum strategy currently rates CG Oncology a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

CG Oncology discussion 0 comments

Add a comment